leadf
logo-loader
viewe-Therapeutics PLC

E-Therapeutics welcomes pharma and biotech veteran to board

E-Therapeutics has hired a pharma and biotech veteran to bolster its focus on commericialising its most promising compounds. Professor Trevor Mervyn Jones CBE, 73, becomes a non-exec director, the AIM firm told investors.

Test-tubes_opt_5631d39fe8c32.jpg
e-Therapeutics announced board changes today...

E-Therapeutics (LON:ETX) has hired a pharma and biotech veteran to bolster its focus on commericialising its most promising compounds.

Professor Trevor Mervyn Jones CBE, 73, becomes a non-exec director, the AIM firm told investors.

Meanwhile, director Dr Rajesh Chopra, has resigned to return to a full-time academic research career.

Chief executive of e-Therapeutics, Professor Malcolm Young, said: "Professor Jones' exceptional research and development experience and illustrious record will be an immensely valuable addition to the team as we ramp up towards realising the commercial potential of our discovery and development assets.

"I would also like to thank Raj Chopra on behalf of e-Therapeutics for his long and considerable contributions to the company and we all wish him well in the next stage of his career.

"The appointment of Professor Jones further supports our new primary focus on commercialising our most promising compounds and programmes."

Jones has over 40 years' distinguished experience in the pharmaceutical and biotech industry as well as in academia. He is the visiting professor at King's College, London and holds honorary degrees from seven universities.

He is currently chairman at contract research organisation Simbec-Orion Group and Welsh investment company, Arthurian Life Sciences.

He was a member of the UK Government Pharmaceutical Industry Ministerial Strategy Working Group on Pharmaceuticals and adviser to the Cabinet Office on the Human Genome Project in 2001.

The group's discovery platform currently has 10 live projects, which will be whittled down for formal pre-clinical development early next year, with the most promising to enter clinical development in 2017.

Currently, there is a phase IIb clinical stage drug candidate for major depressive disorder, ETS6103; and a phase Ib clinical stage candidate in hepatocellular and pancreatic cancer, ETS2101.

Quick facts: e-Therapeutics PLC

Price: 14.375 GBX

AIM:ETX
Market: AIM
Market Cap: £60.24 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of e-Therapeutics PLC named herein, including the promotion by the Company of e-Therapeutics PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read